13 September 2022

NIOX Group plc

("NIOX" or the "Company")

Proposed Capital Reduction Scheme
and
Notice of General Meeting

NIOX Group plc (AIM: NIOX), a company engaged in the design, development and commercialisation of medical devices for asthma diagnosis and management, announces that the Company intends to seek approval from its shareholders and from the High Court to cancel its share premium account in order to create distributable reserves.  This will provide flexibility to enable the Company to return any surplus cash to shareholders in future, whether by paying dividends or buying back its own shares.

While the Company has no immediate plans to return any cash to shareholders, the Directors believe that it is appropriate to restructure the balance sheet to permit them to do so should such plans crystallise in due course.

The proposed capital reduction scheme, in order to take effect, requires shareholders to pass a special resolution at a general meeting of the Company. A circular will shortly be sent to shareholders to convene a general meeting of shareholders on 6 October 2022 (the "General Meeting") in order for them to vote on the Company's proposed capital reduction scheme (the "Circular"). The General Meeting will be held at 10.00 a.m. on 6 October 2022 at the Company's registered office: Hayakawa Building, Edmund Halley Road, Oxford Science Park, Oxford, OX4 4GB.

An electronic copy of the Circular is now available on the Company's website at www.investors.niox.com

If approved by shareholders, the capital reduction scheme will need to be confirmed by the High Court.  It is presently envisaged that the effective date of the capital reduction will be 18 November 2022.

Contacts

NIOX

Ian Johnson, Executive Chairman                                                               Tel: +44 (0) 1865 405 560

Michael Roller, Chief Financial Officer

Singer Capital Markets (Nominated Adviser and Broker)

Aubrey Powell/ Jen Boorer                                                                          Tel: +44 (0) 20 7496 3000

About NIOX

Our ambition is to improve the quality of life of millions of people suffering from asthma. Asthma is one of the biggest healthcare issues globally with 340 million sufferers, many of whom are undiagnosed or misdiagnosed. The Group is engaged in the design, development, and commercialisation of medical devices for the measurement of FeNO, a biomarker of inflammatory asthma. Our market leading device, NIOX VERO®, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis and management of asthma. NIOX VERO® is also the device of choice by leading clinical research organisations for respiratory studies. We passionately believe in empowering everyone to manage their health at home and will look to provide a device designed exclusively for home use. 

At present, NIOX provides products and services in around 50 countries. For more information, please visit www.investors.niox.com

.